Home/Filings/4/0000899243-22-004201
4//SEC Filing

Fenton Mary Kay 4

Accession 0000899243-22-004201

CIK 0001827506other

Filed

Feb 1, 7:00 PM ET

Accepted

Feb 2, 6:00 PM ET

Size

7.3 KB

Accession

0000899243-22-004201

Insider Transaction Report

Form 4
Period: 2022-02-01
Fenton Mary Kay
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-02-01+200,000200,000 total
    Exercise: $9.10Exp: 2032-01-31Common Stock (200,000 underlying)
  • Award

    Common Stock

    2021-12-31$13.00/sh+1,000$13,0001,000 total
Footnotes (2)
  • [F1]These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c).
  • [F2]The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.

Issuer

Talaris Therapeutics, Inc.

CIK 0001827506

Entity typeother

Related Parties

1
  • filerCIK 0001378589

Filing Metadata

Form type
4
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 6:00 PM ET
Size
7.3 KB